Preclinical studies have identified potential mechanisms behind the development of acquired resistance to anti-angiogenic therapy, including adaptive changes in the activation of VEGF-independent angiogenic pathways, altered cellular metabolism and the activation of cancer stem cells [11–13]. Here, VEGFA is linked to cancer.